Silo Pharma, Inc. SILO

NVIDIA partnership boosts Silo Pharma QwikAgents platform and raises prospect of SILO stock as AI investment opportunity. NVIDIA partnership delivers major AI platform upgrade likely to shift company trajectory and investor sentiment.

Silo Pharma's QwikAgents joins AMD AI Developer Program to advance enterprise AI agent platform. AMD AI program membership supports QwikAgents platform development and may lift Silo Pharma innovation and market position.

Silo Pharma, Inc. has successfully closed a registered direct offering, raising $2.5 million priced at-the-market under Nasdaq rules. The offering is expected to enhance the company's financial position and support its ongoing initiatives in the biopharmaceutical sector. The capital raised may moderately influence Silo Pharma's financial performance and operational capabilities.

Silo Pharma, Inc. has updated its strategic agreement with Fireblocks to enhance the security of its cryptocurrency treasury management. This collaboration aims to bolster the company's digital asset management capabilities, ensuring safer transactions and storage of crypto assets. The partnership reflects Silo Pharma's commitment to integrating advanced technology in its operations, potentially improving its financial management and operational efficiency. The strategic agreement with Fireblocks is likely to significantly enhance Silo Pharma's operational security and financial management in the growing cryptocurrency space.

Silo Pharma, Inc. has entered into a strategic agreement with Fireblocks to enhance its cryptocurrency treasury strategy, focusing on acquisition and security measures. This partnership aims to bolster Silo Pharma's capabilities in managing digital assets, ensuring secure transactions, and optimizing treasury operations in the evolving crypto landscape. The strategic agreement with Fireblocks is expected to significantly enhance Silo Pharma's operational capabilities and market positioning in the cryptocurrency sector.

Silo Pharma, Inc. has partnered with Fireblocks to enhance its crypto treasury strategy, focusing on acquisition and security measures. This collaboration aims to improve the management and protection of digital assets, reflecting Silo's commitment to integrating cryptocurrency into its financial operations. The partnership with Fireblocks represents a significant strategic move that could enhance Silo's financial management and investor confidence in the evolving crypto landscape.

Silo Pharma, Inc. has secured a Japanese patent for its licensed PTSD drug, enhancing its global intellectual property portfolio. This addition is part of the company's strategy to expand its market presence and protect its innovations in the treatment of post-traumatic stress disorder. Acquiring a patent in Japan is a significant strategic move that could enhance market opportunities and investor confidence.

Hoth Therapeutics has reported promising results for its antisense therapy targeting KIT-driven cancers, demonstrating efficacy in preclinical studies. The therapy aims to address unmet medical needs in patients with these specific cancer types, potentially offering a new treatment option. Hoth's approach focuses on inhibiting the expression of the KIT gene, which is often mutated in various cancers, leading to tumor growth. The positive outcomes from the studies may pave the way for further clinical development and trials, highlighting the potential of antisense technology in oncology. The development of Hoth's antisense therapy could moderately influence market sentiment and competitive positioning in the oncology sector.

Silo Pharma, Inc. has completed dosing in a safety study for its PTSD drug, SPC-15. This milestone is a significant step in the development of the drug, which aims to address the unmet needs of patients suffering from post-traumatic stress disorder. The company is focused on advancing its clinical programs and enhancing its product pipeline. Completion of dosing in a safety study is a critical milestone that could significantly impact the company's future product development and market positioning.

Silo Pharma, Inc. plans to submit an IND application for its PTSD drug SPC-15 in 2025, pending positive preclinical study results expected in Q3 2025. SPC-15, an intranasal 5-HT4 receptor agonist, aims to address PTSD, a condition with no new drug approvals in nearly 25 years. The company is conducting toxicology studies and a device study for the drug's delivery system. If the IND is approved, a Phase 1 clinical trial could begin by the end of 2026. Silo Pharma is pursuing the FDA's 505(b)(2) regulatory pathway to expedite approval. The company holds exclusive global rights to SPC-15 and collaborates with Columbia University on its development. The planned IND submission and potential Phase 1 trial represent significant strategic moves that could alter the company's trajectory and investor sentiment.

Compass Pathways has achieved the primary endpoint in its COMP360 trial, which focuses on psilocybin therapy for treatment-resistant depression. The results indicate significant improvements in patients, marking a potential breakthrough in psychedelic-assisted therapy. This success may influence future developments in the psychedelic sector and impact related companies, including Silo Pharma, Inc. The positive trial results could enhance market sentiment and competitive positioning for companies in the psychedelic space.

Silo Pharma, Inc. has entered into a Letter of Intent to form a joint venture with Hoth Therapeutics aimed at developing a treatment for obesity, targeting a global market valued at $16 billion. This collaboration is expected to leverage both companies' resources and expertise to address the growing obesity epidemic. The joint venture represents a significant strategic move that could enhance Silo Pharma's market position and financial performance in a lucrative sector.

Hoth Therapeutics and Silo Pharma have formed a 50/50 joint venture to develop a novel GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. This therapy aims to address obesity and fatty liver disease. The joint venture represents a significant strategic move that could enhance Silo Pharma's product offerings and market position.

Silo Pharma secured a patent for an innovative intranasal PTSD treatment, SPC-15, which is set to enter Phase 1 clinical trials. The patent, licensed from Columbia University, covers biomarkers for stress-related disorders and may qualify for expedited FDA approval. Silo is also expanding its strategic initiatives, including a $1 million Bitcoin allocation and partnerships for regulatory compliance. Other notable developments in the cannabis sector include Tilray's approved reverse stock split, 4Front Ventures' bankruptcy filing, and Village Farms regaining Nasdaq compliance. The patent for SPC-15 and its potential FDA approval could significantly enhance Silo Pharma's market position and investor sentiment.

Silo Pharma, Inc. announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent related to its PTSD therapeutic, SPC-15. The patent, expected to be issued on June 17, 2025, strengthens Silo's intellectual property protection for SPC-15, an intranasal treatment for PTSD. CEO Eric Weisblum highlighted the collaboration with Columbia University and NIH support for the patent. Silo holds exclusive rights to develop and commercialize SPC-15 globally, which may benefit from the FDA's streamlined 505(b)(2) regulatory pathway. Silo Pharma focuses on addressing underserved conditions, including PTSD and chronic pain, with a portfolio that includes other innovative programs. The patent issuance and upcoming clinical trials for SPC-15 represent significant strategic advancements for Silo Pharma's product pipeline.

Silo Pharma, Inc. has partnered with Resyca to conduct an IND-supporting study for its intranasal drug SPC-15, aimed at treating PTSD. This collaboration is expected to advance the development of SPC-15 and enhance its potential market entry. The partnership with Resyca for a drug-device study represents a significant strategic move that could impact Silo Pharma's future performance and market positioning.

Silo Pharma, Inc. closed a public offering of 3,333,338 shares of common stock and associated warrants, raising approximately $2 million. The offering was priced at $0.60 per share, with Series A-1 and A-2 Warrants exercisable at the same price. H.C. Wainwright & Co. served as the exclusive placement agent. The proceeds will be used for general working capital. A registration statement was filed and declared effective by the SEC on May 15, 2025. The capital raised may support ongoing development efforts, but the overall impact on the company's trajectory is expected to be limited.

Silo Pharma, Inc. has announced the pricing of a public offering amounting to $2 million. The offering consists of shares of common stock and warrants, aimed at raising capital to support the company's operations and growth initiatives. The shares are expected to be sold at a fixed price, with the offering anticipated to close shortly, subject to customary closing conditions. The public offering may provide necessary capital for operational growth, but its overall impact on the company's trajectory is expected to be limited.

Silo Pharma, Inc. has selected Veloxity Labs to conduct a bioanalytical IND-enabling study for its novel intranasal therapy, SPC-15, aimed at treating PTSD. This collaboration is a significant step in advancing the therapy towards clinical trials, potentially enhancing Silo Pharma's product pipeline and market position in the mental health treatment sector. The collaboration with Veloxity Labs for an IND-enabling study is a major strategic move that could significantly impact Silo Pharma's future product offerings and investor sentiment.

Silo Pharma, Inc. has initiated a 7-day safety and toxicology study for its PTSD treatment SPC-15 in collaboration with Frontage Laboratories, aiming to support its investigational new drug application to the FDA. The company plans to submit the IND this year, with hopes of starting a Phase 1 clinical trial in 2025, pending positive preclinical data. SPC-15, an intranasal serotonin 5-HT4 receptor agonist, targets PTSD and anxiety, and may benefit from the FDA's streamlined 505(b)(2) regulatory pathway. Silo holds exclusive global rights for its development and commercialization. Initiating a safety study and moving towards an IND submission could significantly impact Silo's future product development and market positioning.

Silo Pharma, Inc. announced positive results from a preclinical study of SP-26, an extended-release ketamine implant for fibromyalgia. The study met all endpoints, demonstrating strong tolerability, sustained drug release, and safety in minipigs. SP-26 aims to provide a controlled delivery of ketamine, avoiding the dissociative effects of IV injections and offering an alternative to opioids. The results position Silo to advance toward clinical studies and potentially qualify for the FDA’s 505(b)(2) regulatory pathway for drug approval. Positive preclinical results for SP-26 could significantly enhance Silo's product pipeline and market position in chronic pain management.

Silo Pharma, Inc. has filed a patent application with the U.S. Patent and Trademark Office for SPC-14, an intranasal drug for treating Alzheimer's disease, exclusively licensed from Columbia University. The patent covers SPC-14's mechanism targeting glutamate receptor NDMAR and serotonin 5-HT4, which has shown efficacy in pre-clinical studies for cognitive and neuropsychiatric symptoms. CEO Eric Weisblum emphasized the importance of this patent for the company's intellectual property strategy. Silo Pharma aims to develop, manufacture, and commercialize SPC-14 under a global license agreement with Columbia University. The patent application for SPC-14 represents a significant strategic move that could enhance Silo Pharma's product offerings and market position in the Alzheimer's treatment space.

Silo Pharma, Inc. has achieved a significant milestone by initiating the first dosing in an IND-enabling GLP study for its PTSD treatment candidate, SPC-15. This advancement marks a crucial step in the development of innovative therapies aimed at addressing post-traumatic stress disorder, potentially positioning Silo Pharma as a key player in the mental health treatment market. The initiation of the GLP study for SPC-15 represents a major strategic move that could significantly impact Silo Pharma's future performance and investor sentiment.

Silo Pharma (SILO) received an Issue Notification for a patent titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' reinforcing protection for its lead asset, SPC-15, an intranasal treatment for PTSD. The patent, projected to be numbered 12,239,614, will be issued on March 4 and expands coverage for SPC-15, which is in collaboration with Columbia University. Meanwhile, GH Research (GHRS) and Compass Pathways (CMPS) reported their earnings, with both companies facing losses but making progress in their clinical trials and financial positions. The patent issuance for SPC-15 significantly enhances Silo Pharma's competitive position and potential for future clinical trials.

Silo Pharma, Inc. announced that the U.S. Patent and Trademark Office issued an Issue Notification for patent application No. 17/954,864, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' with a projected patent number of 12,239,614, effective March 4, 2025. This patent enhances protection for Silo's lead asset, SPC-15, an intranasal treatment for PTSD, and includes new claims to a previously issued patent. CEO Eric Weisblum emphasized the importance of strategic IP expansion for advancing SPC-15 to clinical trials. SPC-15 is a serotonin 5-HT4 receptor agonist with potential for expedited FDA approval. Silo is collaborating with Columbia University on preclinical studies and holds exclusive global rights for SPC-15's development and commercialization. The issuance of a new patent significantly strengthens Silo's position in the PTSD treatment market and supports its clinical development efforts.

Silo Pharma, Inc. has filed a provisional patent application for its SPC-15 combination treatment, which targets stress-induced psychiatric disorders. The provisional patent covers a dual-action method for reducing stress-induced behaviors. Preclinical studies show that SPC-15, a serotonin 5-HT4 receptor agonist, combined with an NMDAR antagonist, significantly improves behavioral outcomes. The company aims to expedite the approval process through the FDA’s 505(b)(2) pathway. Silo has exclusive global rights to develop and commercialize SPC-15, which is part of its broader portfolio addressing various CNS diseases. The provisional patent filing and promising preclinical results could significantly enhance Silo's product pipeline and market positioning.

Silo Pharma, Inc. announced positive results from an ongoing study of its SP-26 ketamine extended-release rods for chronic pain and fibromyalgia. The study, which began in December 2024, showed no serious side effects in animal testing, with final safety and pharmacokinetic data expected in March 2025. SP-26 is designed as a self-administered, non-opioid treatment that could qualify for the FDA’s 505(b)(2) regulatory pathway if successful. Positive initial results from the SP-26 study could significantly influence Silo Pharma's future product offerings and market position.

Silo Pharma, Inc. has filed a provisional patent for a treatment aimed at post-traumatic stress disorder (PTSD). This move is part of the company's strategy to enhance its intellectual property portfolio, potentially positioning it for future advancements in the mental health treatment sector. The provisional patent filing for PTSD treatment represents a significant strategic move that could enhance Silo Pharma's competitive positioning and market opportunities.

Silo Pharma, Inc. has been awarded a U.S. patent for its innovative treatment aimed at addressing post-traumatic stress disorder (PTSD). This patent is expected to enhance the company's position in the mental health treatment market and may lead to further developments in their therapeutic offerings. The patent award is likely to significantly impact Silo Pharma's future performance and market positioning in the mental health sector.

Silo Pharma, Inc. has been awarded a US patent for its innovative treatment targeting PTSD, marking a significant advancement in the field. The company is now preparing to initiate clinical trials for its SPC-15 treatment, which aims to address the needs of individuals suffering from this condition. This development positions Silo Pharma at the forefront of PTSD research and treatment. The patent award and upcoming clinical trial for SPC-15 are likely to significantly impact Silo Pharma's future performance and market positioning in the mental health treatment sector.